Histopathological Profile of Uterine Adnexal Masses and Correlation with Serum CA 125 of Benign & Malignant Adnexal Masses

Authors
Jinia Das¹*, Tushar Kanti Das², R.P. Ganguly³
*Corresponding Author

Jinia Das
91/C/ 27 , Motilal Gupta Road, Pramod Nagar, P.O. Haridevpur, Kolkata 700082, India
Email: jinia_das@hotmail.com, Phone no. 8777294506

Abstract
The detection of uterine adnexal mass with associated raised serum CA 125 level is highly suspicious for ovarian cancer, but there are various other benign and malignant adnexal pathologies that mimic the above findings, especially in premenopausal women in our country as seen in our case study. The aims and objectives of this study were to study the histopathological spectrum of uterine adnexal mass and correlation of serum CA125 with benign & malignant masses, determine the incidence rate, age distribution and histopathological pattern of adnexal mass in operated specimens, to study the frequency of benign and malignant neoplasms of ovary in this region and also to study the cut off values of Serum CA-125 in Benign and Malignant ovarian lesions. The present study had revealed various facets of epithelial ovarian tumours keeping comparable results with different studies. Among all cases 64.71% of the cases were benign, 5.88% borderline and 29.41% malignant. Benign tumours clustered a decade earlier than malignant tumours. The epithelial tumours are the most common tumours. Unless better methods of prevention, early diagnosis and/or curative treatment are introduced, a gradual rise in the mortality rate from uterine adnexal cancer, especially ovarian cancer is expected in this country.

Introduction
Uterine adnexa refers to adjoining anatomical parts of the uterus. It includes the fallopian tubes and ovaries and associated vessels, ligaments and connective tissues.¹
Mass usually originates from ovary or fallopian tube. However, it may arise from various other mentioned structures. Any lump or mass found within adnexa of uterus is abnormal and needs to be evaluated.² They may be benign or malignant.³ Adnexal masses present a diagnostic dilemma; the differential diagnosis is extensive, and most masses are benign¹²³. However, without histopathological diagnosis, a definitive diagnosis is generally precluded.
Uterine adnexal mass, especially ovarian cancer popularly known as ‘the silent killer’, is a dreaded disease because of its vague, non-specific symptoms and late presentation. Worldwide, it is the ⁷th most common cause of cancer and ⁸th most common cause of cancer related death among women¹.
Incidence of uterine adnexal cancer in India is lower than that of Western countries. The present study was undertaken to assess the situation of adnexal tumours tumours, not only cancers but
also benign as well as borderline tumours, among patients admitted in this hospital and correlation serum CA 125 was analysed for early detection of cancer.

In the past, physicians relied on the findings of a pelvic examination to diagnose an adnexal mass. With the introduction of imaging modalities including transabdominal and vaginal ultrasonography, Doppler colour scans, and MRI, more characterization of the internal structure of the mass (i.e., wall complexity, mass contents) is possible.

In girls younger than 9 years, 80% of ovarian masses are malignant and are generally germ cell tumours. During adolescence, 50% of adnexal neoplasms are mature cystic teratomas or dermoid cysts. In sexually active adolescents, one must always consider a tubo-ovarian abscess as the cause of an adnexal mass.

In women of reproductive age who have had adnexal masses removed surgically, most are benign cysts or masses, 10% of masses are malignant. Serum CA 125 is an antigenic determinant on a high–molecular-weight glycoprotein recognized by a monoclonal antibody (OC 125). The full-length CA 125 glycoprotein contains more than 11,000 amino acids in its proteinaceous core and has been termed Muc16 to reflect the mucin like nature of the antigen and is now identified as a new member of the protein family of mucins.

CA 125 is expressed by more than 80% of non-mucinous epithelial ovarian carcinomas and is found in most carcinomas of Mullerian origin, including fallopian tube and primary serous peritoneal carcinoma. In addition, it can be expressed by several benign and physiologic conditions also. Serum CA 125 is the only tumour marker recommended for clinical use in the diagnosis and management of ovarian cancer mainly. CA 125 is the only tumour marker recommended for clinical use in the diagnosis and management of cancer. Declining CA 125 levels have been shown to correlate with treatment response, even when disease is not detectable with physical examination or imaging. In this setting, serial CA 125 testing has more clinical utility than a single determination.

Material and Methods
The case series include those cases (234 cases) that presented between April 2016-March 2017 at our institution as resected specimen of uterine adnexal mass and correlated with elevated serum level of CA125, however on complete workup by radiological investigations (USG/CT scan/MRI Scan), diagnostic laparoscopy/therapeutic laparotomy with histopathology examination of operative specimen or biopsy material. The Serum CA 125 level more than 35 units/ml was considered as elevated.

Statistical Analysis
We found total 234 cases of uterine adnexal masses, including benign, borderline and malignant types. The detailed results were as follow:

Parameters
Regarding age, 72.06% of all cases were from 30 – 59 years. Maximum number of cases were in 4th decade (25%), followed by equal number of cases in 5th and 6th decade (23.53%). The youngest and oldest members of the study population were 14 years and 80 years old respectively. Mean age of presentation was 36 years, median 46 years, standard deviation 18.05.
Table 1: Distribution of Adnexal Mass in Total Population According To Age (N=234)

| Age (Years) | Patients | Number | Percentage (%) |
|-------------|----------|--------|----------------|
| 9 - 9       |          | 0      | 0.00           |
| 10 - 19     |          | 4      | 1.70           |
| 20 - 29     |          | 45     | 19.23          |
| 30 - 39     |          | 60     | 25.64          |
| 40 - 49     |          | 55     | 23.50          |
| 50 - 59     |          | 55     | 23.50          |
| 60 - 69     |          | 17     | 7.26           |
| **Total**   |          | 234    | 100.00         |

Table 2: Distribution of the Benign Lesions According To Age (n=154)

| Age (yr)  | Serous | Mucinous | Endometrical | Germinal | SC | Total |
|-----------|--------|----------|--------------|----------|----|-------|
| 0-9       | 0 (0%) | 0 (0%)   | 0 (0%)       | 0 (0%)   | 0  | 0 (0%)|
| 10-19     | 6 (38.8%) | 3 (18.8%) | 0 (0%) | 9 (57.1%) | 0  | 13 (8.9%)|
| 20-29     | 12 (16.2%) | 7 (20%) | 2 (40%) | 4 (28.6%) | 1 (10%) | 18 (12.3%)|
| 30-39     | 42 (41.46%) | 9 (28.65%) | 0 (0%) | 6 (57.1%) | 1 (10%) | 52 (33.7%)|
| 40-49     | 18 (21.23%) | 4 (14.76%) | 0 (0%) | 2 (10%) | 0 (0%) | 28 (14.9%)|
| 50-59     | 14 (16.23%) | 7 (20%) | 0 (0%) | 0 (0%) | 0 (0%) | 19 (12.3%)|
| 60-69     | 3 (4.85%) | 2 (8.88%) | 1 (60%) | 0 (0%) | 0 (0%) | 5 (3.2%)|
| **Total** | 91 (100%) | 32 (100%) | 3 (100%) | 14 (100%) | 2 (100%) | 154 (100%)|

Table 3: Distribution of Malignant Tumours According to Age (n=66)

| Age (yr)  | Serous | Malignant | Endo Peritoneal | Germinal | Sex cord | Metastatic | Number |
|-----------|--------|-----------|----------------|----------|----------|------------|--------|
| 0-9       | 0 (0%) | 0 (0%)    | 0 (0%)         | 0 (0%)   | 0 (0%)   | 0 (0%)     | 0 (0%) |
| 10-19     | 0 (0%) | 0 (0%)    | 0 (0%)         | 0 (0%)   | 0 (0%)   | 0 (0%)     | 0 (0%) |
| 20-29     | 0 (0%) | 0 (0%)    | 0 (0%)         | 1 (33%)  | 0 (0%)   | 0 (0%)     | 1 (1.5%)|
| 30-39     | 7 (14.2%) | 3 (25%) | 0 (0%) | 2 (66%) | 1 (33%) | 1 (33%) | 15 (22.7%)|
| 40-49     | 19 (42.8%) | 5 (50%) | 2 (0%) | 1 (33%) | 0 (0%) | 2 (50%) | 28 (42.3%)|
| 50-59     | 14 (37.7%) | 1 (25%) | 2 (100%) | 0 (0%) | 0 (0%) | 0 (100%) | 19 (28.7%)|
| 60-69     | 3 (7.14%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 3 (4.5%)|
| **Total** | 44 (100%) | 9 (100%) | 1 (100%) | 3 (100%) | 3 (100%) | 2 (100%) | 66 (100%)|
Data analysis shows that P value is < .05, so it is a significant study.

**Investigation Findings**

We studied the cases according to serum CA125 level. Among the benign tumours, there were 32 cases of benign tumours (19.09%) including 21 serous and 8 mucinous cystadenoma, which had high CA125 level. Among 3 cases of Brenner tumour, 1 had CA125 level of 79.83 U/ml. Rest 6 cases had CA125 level slightly raised than normal range of <35 U/ml. The highest level of CA125 noted, among the benign tumours in the study population, was 702.9 U/ml, found in a case of serous cystadenofibroma. We found that in all cases of malignant tumours CA125 levels were raised. Lowest level noted among carcinomas was 44.3 U/ml, detected in a mucinous carcinoma. Mucinous carcinomas though had raised CA125 levels, but these were less than that of serous carcinomas. The highest level was 4500 U/ml, found in a serous carcinoma. Among the fourteen borderline tumours, 3 had CA125 level<35 U/ml and one had 44.8 U/ml.

**Table 5:** Distribution of Patients with Benign Tumour According to Serum CA125 Level (n=154)
Table 6: Distribution of Patients with Borderline and Malignant Tumours According To Serum CA125 Level (n=80)

Table 7: malignancy and serum marker cross tabulation

Case Processing Summary

| Cases          | Valid | Missing | Total |
|----------------|-------|---------|-------|
|                | N     | Percent | N     | Percent |
| MALIGNANCY * MARKER | 234   | 100.0%  | 0     | 0.0%    |
|                | 234   | 100.0%  |       |         |

MALIGNANCY * MARKER Crosstabulation

| MARKER          | LESS THAN 35 | 35 AND ABOVE | Total |
|-----------------|--------------|--------------|-------|
|                 | Count        | Expected Count |       |
| POSITIVE        | 14           | 40.1         | 61    |
| NEGATIVE        | 140          | 113.9        | 173   |
| Total           | 154          | 154.0        | 234   |

Chi-Square Tests

|                | Value   | df | Asymp. Sig. (2-sided) | Exact Sig. (2-sided) | Exact Sig. (1-sided) |
|----------------|---------|----|-----------------------|----------------------|----------------------|
| Pearson Chi-Square | 67.367a | 1  | .000                 |                      |                      |
| Continuity Correctionb | 64.815 | 1  | .000                 |                      |                      |
| Likelihood Ratio   | 66.256  | 1  | .000                 | .000                 | .000                 |
| Fisher's Exact Test| 67.079  | 1  | .000                 |                      |                      |
| Linear-by-Linear Association | 234     | 1  | .000                 |                      |                      |

a. 0 cells (.0%) have expected count less than 5. The minimum expected count is 20.85.
b. Computed only for a 2x2 table
Histopathological Findings
We found that majority of the tumours were benign in nature (64.71%). Malignant tumours constituted 28.41% of total population. 5.88% of the cases were of borderline type. Among benign tumours, 59.09% were serous tumours and 20.12% were benign mucinous tumours. Only three cases of Brenner tumour were noted in the study population. Among the benign serous tumours, most common tumour type was serous cystadenoma, constituting 59.09% among the benign serous group, followed by serous cystadenofibroma belonging to 1.4%. The most common type of malignant tumour was serous cystadenocarcinoma, constituting 66.7% of all carcinomas, followed by mucinous cystadenocarcinoma (13.7%). Three cases (4.5%) each of endometrioid carcinoma and of clear cell carcinoma were detected among the malignant tumours.
Overall, serous tumour was most prevalent, constituting 58.82% of the total population studied. Among the serous tumours, 65% were benign and 35% were malignant. Next most common type was mucinous tumour, constituting 36.76% of total population. It had 68% of benign, 16% each of borderline and malignant tumour types. Endometrioid carcinoma was detected in three case (1.47% of the total population). Three cases were of transitional type (1.94%), germ cell tumour /mal (4.5%) and two cases of sex-cord stromal tumour /mal (3.15%) of the total population.

Table 8: Distribution of Patients According to Nature of Tumours (N=234)

| Nature of tumours | Patients |
|-------------------|----------|
|                   | Number   |
| Benign            | 154      |
| Borderline        | 14       |
| Malignant         | 66       |
| Total             | 234      |

| Nature of tumours | Percentage (%) |
|-------------------|----------------|
| Benign            | 64.71 (%)      |
| Borderline        | 5.88 (%)       |
| Malignant         | 29.41 (%)      |
| Total             | 100 (%)        |

Table 9: Distribution of Benign Tumours According To Types (n=154)

| Types of benign tumours | Patients |
|-------------------------|----------|
|                         | Number   |
| Serous                  | 91       |
| Mucinous                | 32       |
| Brenner                 | 3        |
| Mature cystic teratoma  | 14       |
| Endometriocytoma (Choctolate cyst) | 12 |
| Cystadenofibroma        | 2        |
| Total                   | 154      |

| Types of benign tumours | Percentage (%) |
|-------------------------|----------------|
| Serous                  | 59.09 (%)      |
| Mucinous                | 20.12 (%)      |
| Brenner                 | 1.9 (%)        |
| Mature cystic teratoma  | 9.7%           |
| Endometriocytoma (Choctolate cyst) | 7.7% |
| Cystadenofibroma        | 1.4%           |
| Total                   | 100%           |

Table 10: Distribution of Malignant Tumours According to Tumours Types (n=66)

| Types of tumours | Patients |
|------------------|----------|
|                  | Number   |
| Serous            | 44       |
| Mucinous          | 9        |
| Endometrioid adenocarcinoma | 3 |
| Clear cell carcinoma | 3   |
| Germ cell tumour (Mal) | 2   |
| Seroli-Leidig cell tumour | 2   |
| Dysgerminoma      | 1        |
| Undifferentiated/Krukenburg tumour | 2 |
| Total             | 66       |

| Types of tumours | Percentage (%) |
|------------------|----------------|
| Serous            | 66.7 (%)       |
| Mucinous          | 13.7 (%)       |
| Endometrioid adenocarcinoma | 4.5% |
| Clear cell carcinoma | 4.5% |
| Germ cell tumour (Mal) | 3.15% |
| Seroli-Leidig cell tumour | 3.15% |
| Dysgerminoma      | 1.15%          |
| Undifferentiated/Krukenburg tumour | 3.15% |
| Total             | 100%           |
Result
In short, the present study had revealed various facets of epithelial ovarian tumours keeping comparable results with different studies. These findings need to be confirmed by a larger prospective cohort.
1. Benign tumours clustered a decade earlier than malignant tumours. Main bulk of malignant tumours (80%) was in 5\textsuperscript{th} & 6\textsuperscript{th} decade, in contrast to benign tumours where main bulk (56.82%) was in 3\textsuperscript{rd} & 4\textsuperscript{th} decade.
2. 64.71% of the cases were benign, 5.88% borderline and 29.41% malignant. Overall, serous tumours were the most prevalent one, constituting 58.82% of the total population studied, of which 65% were benign and 35% were malignant.
3. Among the malignant tumours 60% presented in advanced stage (III & IV), of which 95% were serous carcinomas. 4.92.86% of the serous carcinomas were of high grade, of which 71.43% were of advanced stage (III & IV).
5. Unilateral ovarian tumours were more common, constituting 82.35% of total population than bilateral tumours for benign, borderline as well as malignant tumours.
6. Among the tumours 25% were partly solid partly cystic, of which 76.47% cases were malignant. The tumours that were completely solid (7.35%), all were malignant.
7. We studied the cases according to serum CA125 level. Among the benign tumours, 71% of the cases had CA125 level <30 U/ml. However, there were 32 cases of benign tumours (19.09%) including 21 serous and 8 mucinous cystadenoma which had high CA125 level.
8. When we analysed the malignant tumours, we found that in all cases of malignant tumours CA125 levels were raised. Lowest level among
carcinomas was 44.3 U/ml, detected in a mucinous carcinoma. Mucinous carcinomas though had raised CA125 levels, but these were lesser than that of serous carcinomas. The highest level was 9900 U/ml, found in a serious carcinoma. Among the fourteen borderline tumours, 3 had CA125 level <35 U/ml and one had 44.8 U/ml. CA 125 is the only marker recommended for clinical use in the diagnosis and management of ovarian cancer mainly. There are many indications in which the determination of CA 125 levels is recommended.

Discussion
The spectrum of uterine adnexal masses is very wide. In the present study total 234 patients admitted in the Department of G&O, R G Kar Medical College & Hospital, Kolkata, selected by the predetermined sampling technique were incorporated. This observational, descriptive, cross-sectional study has pointed out certain important characteristics of uterine adnexal masses. Present study results have been compared to different published studies over different parameters. Our study results matched with the studies done by Lataifeh et al (2005)24, Goff et al (2000)25. All of them described pain abdomen as the most common presenting complaint. They described 12.3% of the cases presented with abnormal bleeding PV which was very close to our results. Our study results corroborated with Mondal et al (2011)25, where they described mean age 47 years for benign tumours and 55.4 years for malignant tumours and Rubin et al (1994)26 where the mean age of the patients with early epithelial ovarian cancers (stage I and II) was 53 years. Small sample size, limited study duration might be the reason behind this disparity. Our study results corroborated with Risch et al (1996)18 where they revealed that increase in parity was associated with significant protective trends in risk. It is well accepted fact that incidence of ovarian tumour increases with decrease in parity, that is explained by incessant ovulation theory. Our study results had not differed from it showing more cases in lower parity and lesser number of cases in higher parity. Our study results corroborated with Morrow et al26 where they described that among the benign serous tumours 20% were bilateral and among the malignant serous tumours 50% were bilateral. The results corroborated with Kawamoto et al29 where they described 60% of the epithelial ovarian tumours were benign, 35% malignant, 5% of low-malignant-potential (borderline) type. The present study echoed with McCluggage (2011)30 where 68-71% of ovarian carcinomas were of serous type. Our study corroborated with Phukan et al (2013)31 where about 59.1% cases were at advanced stage (III & IV). Our study corroborated with study of WHO32 classification of tumours of female reproductive organs, where leiomyoma is the most common solid tumour of broad ligament and most common cystic tumour is serous cystadenoma.

Conclusion
With our currently expanding elderly population, diseases that become progressively more frequent with aging are expected to expand in number in near future. Unless better methods of prevention, early diagnosis &/or curative treatment are introduced, a gradual rise in the mortality rate from uterine adnexal cancer, especially ovarian cancer is expected in this country. The challenge for the next decade would be to use rational combinations offering maximal clinical benefit at minimal cost. The challenge is obvious, as early diagnosis of ovarian carcinoma is a tough job, due to non-specific symptoms. Over the past several years, significant progress has been made in the treatment. Conventional modality of treatment is cytoreductive surgery, followed by carboplatin and paclitaxel. Neoadjuvant chemotherapy, followed by interval debulking and post-surgery chemotherapy, is preferred for advanced stage carcinomas. However, development of novel therapeutic
approaches is the need of the hour, as we have to minimise chemotoxicity. With increasing knowledge of serum marker study, immunology, and targeted therapy, we are able to see some light at the end of the tunnel. The present study has laid, to some extent, the groundwork necessary to begin such newer approaches against ovarian carcinomas.

We were severely constrained by limited study duration, small sample size, which we need to overcome, to obtain the exact impression among general population at large.

We can conclude from our discussion that ultrasonography is definitely an important non-invasive investigation and is helpful in diagnosing most cases of functional ovarian cysts, benign ovarian neoplasm and ovarian malignancy; but the histopathological examination of specimen obtained from laparotomy/laparoscopy of adnexal mass is the gold standard for confirming the diagnosis. Although bimanual palpation of the adnexal masses may not allow a very specific diagnosis, clinically useful information can usually be obtained and hence it is particularly useful as a first step in assessment of adnexal masses and as an adjunct to morphological assessment of ovarian lesions. However no single diagnostic aid can be used to determine the pathological adnexal masses. Hence a multifaceted diagnostic approach should be used for a definite diagnosis and management of uterine adnexal mass.

References
1. ACOG Practice Bulletin. Evaluation and Management of adnexal masses. Obstet Gynecol. 2016 Nov. 128(5):e210-226.
2. Drake J. Diagnosis and management of the adnexal mass. Am Fam Physician. 1998 May 15. 57(10):2471-6, 2479-80.
3. Gallup DG, Talledo E. Management of the adnexal mass in the 1990s. South Med J. 1997 Oct. 90(10):972-81.
4. Sayasneh A, Ekechi C, Ferrara L, et al. The characteristic ultrasound features of specific types of ovarian pathology (Review). Int J Oncol. 2015 Feb. 46(2):445-58.
5. Hricak H, Chen M, Coakley FV, et al. Complex adnexal masses: detection and characterization with MR imaging--multivariate analysis. Radiology. 2000 Jan. 214(1):39-46.
6. Alcazar JL, Ruiz-Perez ML, Errasti T. Transvaginal color Doppler sonography in adnexal masses: which parameter performs best?. Ultrasound Obstet Gynecol. 1996 Aug. 8(2):114-9.
7. Castillo G, Alcázar JL, Jurado M. Natural history of sonographically detected simple unilocular adnexal cysts in asymptomatic postmenopausal women. Gynecol Oncol. 2004 Mar. 92(3):965-9.
8. Modesitt SC, Pavlik EJ, Ueland FR, DePriest PD, Kryscio RJ, van Nagell JR Jr. Risk of malignancy in unilocular ovarian cystic tumors less than 10 centimeters in diameter. Obstet Gynecol. 2003 Sep. 102(3):594-9.
9. Zalel Y, Piura B, Elchalal U, Czernobilsky B, Antebi S, Dgani R. Diagnosis and management of malignant germ cell ovarian tumors in young females. Int J Gynaecol Obstet. 1996 Oct. 55(1):1-10. [Medline].
10. Barber HR, Graber EA. Gynecological tumors in childhood and adolescence. Obstet Gynecol Surv. 1973 May. 28(5):suppl:357-81.
11. Pfeifer SM, Gosman GG. Evaluation of adnexal masses in adolescents. Pediatr Clin North Am. 1999 Jun. 46(3):573-92.
12. Slap GB, Forke CM, Cnaan A, et al. Recognition of tubo-ovarian abscess in adolescents with pelvic inflammatory disease. J Adolesc Health. 1996 Jun. 18(6):397-403.
13. Kinkel K, Lu Y, Mehdizade A, Pelte MF, Hricak H. Indeterminate ovarian mass at US: incremental value of second imaging test for characterization--meta-analysis and Bayesian analysis. Radiology. 2005 Jul. 236(1):85-94.
14. Russo A, Calò V, Bruno L, Rizzo S, Bazan V, Di Fede G. Hereditary ovarian cancer. Crit Rev Oncol Hematol. 2008 Jul 23.
15. Lancaster JM, Powell CB, Chen LM, Richardson DL, SGO Clinical Practice Committee. Society of Gynecologic Oncology statement on risk assessment for inherited gynecologic cancer predispositions. Gynecol Oncol. 2015 Jan;136(1):3-7.

16. Plon SE, Cooper HP, Parks B, Dhar SU, Kelly PA, Weinberg AD, et al. Genetic testing and cancer risk management recommendations by physicians for at-risk relatives. Genet Med. 2011 Feb;13(2):148-54.

17. NCCN. Genetic/Familial High-Risk Assessment: Breast and Ovarian. NCCN Clinical Practice Guidelines in Oncology. Version 2.2015. NCCN; 2015.

18. Risch HA, McLaughlin JR, Cole DE, Rosen B, Bradley L, Kwan E. Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer. Am J Hum Genet. 2001 Mar;68(3):700-10.

19. Pal T, Permuth-Wey J, Betts JA, Krischer JP, Fiorica J, Arango H. BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma cases. Cancer. 2005 Dec 15;104(12):2807-16.

20. Press JZ, De Luca A, Boyd N, Young S, Troussard A, Ridge Y. Ovarian carcinomas with genetic and epigenetic BRCA1 loss have distinct molecular abnormalities. BMC Cancer. 2008; 8:17.

21. The Million Women Study: design and characteristics of the study population. The Million Women Study Collaborative Group.Breast Cancer Res 1999;1(1):73-80.

22. Hays J, Hunt JR, Hubbell FA, Anderson GL, Limacher M, Allen C, et al. The Women's Health Initiative recruitment methods and results. Ann Epidemiol 2003; 13(9 Suppl):S18-77.

23. ROBERT V. KREJCIE University of Minnesota, Duluth DARYLE W. MORGAN Texas A. & M. University https://home.kku.ac.th/sompong/guest_speaker/KrejcieandMorgan.

24. Lefebvre R, Chenoweth PJ, Drost M, et al. Characterization of the oviductal sperm reservoir in cattle. Biol Reprod. 1995 Nov;53(5):1066-74.

25. Goff BA, Mandel LS, Melancon CH, Muntz HG. Frequency of symptoms of ovarian cancer in women presenting to primary care clinics. JAMA. 2004;291(22):2705-2712.

26. Rubin SC, Finstad CL, Federici MG, Lloyd KO, Hoskins WJ. Prevalence and Significance of HER-2/neu Expression in Early Epithelial Ovarian Cancer. Cancer 1994;73:1456

27. Gong TT, Wu QJ, Vogtmann E, Lin B, Wang YL. Age at menarche and risk of ovarian cancer: a meta-analysis of epidemiological studies. Int J Cancer 2013 Jun 15;132(12):2894-900

28. Wagner BJ, Buck JL, Seidman JD, McCabe KM. Ovarian epithelial neopl-asms: radiologicpathologic correlation. Radio Graphics 1994;14:1351–1374

29. Maxim AR, Coadă CA, Badea RI. Ovarian cancer experience from a Romanian regional center: preliminary results. HVM Bioflux 2013;5

30. Mccluggage WG. Morphological subtypes of ovarian carcinoma: a review with emphasis on new developments and pathogenesis. Pathology August 2011;43(5):420–432 3):109-113

31. Phukan JP, Sinha A, Sardar R, Guha P. Clinicopathological analysis of ovarian tumors in perimenopausal women: A study in a rural teaching hospital of eastern India. Bangladesh Journal of Medical Science 2013 July;12(03):263-268

32. WHO Classification of Tumours of Female Genital Tract, 2014.